The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. 

In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. 

Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Shares have formed a bullish "flag." We expect higher share prices. On November 9th, IMCR reported 3rd Quarter September 2022 earnings of $0.14 per share on revenue of $48.5 million. The consensus estimate was a loss of $0.26 per share on revenue of $37.7 million. Revenue grew 493.9% on a year-over-year basis.

• Entry Point: $59.20
• Stop Loss: $56.40
• Trading Range: $20.02 to $69.05
• Target Price: $65.00